Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

DeepVerge plc debtor

18 Apr 2023 07:59

RNS Number : 5723W
Microsaic Systems plc
18 April 2023
Β 

18 April 2023

Β 

Microsaic Systems plc

Β 

("Microsaic" or the "Company")

Β 

DeepVerge plc ("DeepVerge") debtor

Β 

Β 

Further to yesterday's announcement by DeepVerge[1], Microsaic (AIM: MSYS) notes that material sums are owed by DeepVerge group companies to Microsaic, totalling approximately Β£1.4 million as at today's date which largely relates to the supply of goods and services recognised as revenues for the financial year ended 31 December 2022 ("FY22"). The balance outstanding has reduced from approximately Β£1.5 million at 31 December 2022 following receipt of certain payments from DeepVerge.

Β 

A settlement plan has been proposed by DeepVerge to Microsaic, the terms of which are substantially agreed subject to clarification in respect of suitable potential security for the balances due. DeepVerge has made an initial payment in line with that plan, the value of which exceeds Β£0.1 million. In addition, Microsaic has continued to supply services to DeepVerge during 2023, and all amounts arising during the current financial year continue to be received by Microsaic under normal 30-day terms, in line with commercial agreements between the two parties.

Β 

Microsaic has cash of Β£0.8 million as of 17 April 2023 and is due to receive R&D tax credits in respect of 2021 and 2022 totalling circa Β£0.5 million, as well as the outstanding DeepVerge balance of Β£1.4 million. Although the first quarter of trading in the current year has started slowly, Microsaic has a growing sales pipeline currently worth in excess of Β£2 milllion, over 90% of which is from customers or distribution channels other than DeepVerge. This reflects the continual sales effort to cultivate and expand the Company's relationships with current customers, while also actively pursuing new business opportunities. A mixture of prospective repeat sales and new revenue streams are therefore expected to support Microsaic's continuing sales progress in 2023 and beyond.

Microsaic expects to release its audited financial results for the year ended 31 December 2022 (the "FY22 Results") during the first half of May 2023. The phasing and quantities of receipts from DeepVerge in relation to this historic commercial debt will be subject to further discussion with the Company's auditors, and appropriate disclosures will be included within the FY22 Results.Β 

Β 

Enquiries:

Β 

Microsaic Systems plc

+44 (0) 734 0055 648

Gerry Brandon, Acting Executive Chairman

Β 

Β 

Singer Capital Markets (Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell / George Tzimas

Β 

Β 

Turner Pope Investments (TPI) LimitedΒ (Joint Broker)

Andy ThackerΒ /Β James Pope

+44 (0) 20 3657 0050

Β 

Β 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information as stipulated under theΒ UKΒ version of the market abuse regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Β 

About Microsaic Systems

MicrosaicΒ floated on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested c.Β Β£30mΒ over 20 years of development,Β MicrosaicΒ has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application.Β MicrosaicΒ serves markets in Human Health,Β Environmental Health and Diversified Industries.Β Microsaic'sΒ system solutions enable analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous MS detection data at multiple steps in the process workflow.

Β 

Microsaic'sΒ products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point of need applications.Β 

Β 

Β 


[1] https://www.londonstockexchange.com/news-article/DVRG/2022-revenue-update-revision/15917630

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCKZGMDVRRGFZG
Date   Source Headline
24th Nov 20222:00 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
13th Sep 20227:25 amRNSSupply of mass spectroscopy services to DeepVerge
22nd Aug 20227:00 amRNSPartnership with Kingfield Electronics
5th Jul 20224:41 pmRNSSecond Price Monitoring Extn
5th Jul 20224:35 pmRNSPrice Monitoring Extension
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:01 pmRNSPrice Monitoring Extension
4th Jul 20224:43 pmRNSReplacement: Trading Update
1st Jul 20222:09 pmRNSHolding(s) in Company
30th Jun 202212:11 pmRNSResult of AGM
30th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSFinal Results
19th Apr 20227:00 amRNSManufacturing Services Framework Agreement
28th Mar 20227:30 amRNSUpdate on Microsaic's miniaturised technology
15th Mar 20227:00 amRNSBoard Appointment and Strategic Update
8th Mar 20224:35 pmRNSPrice Monitoring Extension
7th Mar 20222:05 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20221:31 pmRNSHolding(s) in Company
17th Feb 20222:45 pmRNSHolding(s) in Company
16th Feb 202211:06 amRNSSecond Price Monitoring Extn
16th Feb 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSDirector Dealing, Issue of Equity and TVR
28th Jan 20227:00 amRNSResignation of Chief Executive Officer
12th Jan 20224:43 pmRNSHolding(s) in Company
10th Jan 20223:30 pmRNSInvestor Presentation
10th Jan 20227:00 amRNSTrading Update
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSFurther order from DeepVerge
12th Nov 20217:00 amRNSNew compact screening platform
5th Nov 202110:12 amRNSHolding(s) in Company
27th Oct 20217:00 amRNSLaunch of technology for scaling drug manufacture
22nd Oct 20217:00 amRNSBoard Change
21st Oct 20217:00 amRNSUpdate on DeepVerge Collaboration
28th Sep 20214:30 pmRNSHolding(s) in Company
27th Sep 20217:00 amRNSInterim Results
24th Sep 20217:00 amRNSSigning of agreement to support China operations
22nd Sep 202111:06 amRNSNotice of Results and Investor Presentation
27th Aug 20214:40 pmRNSSecond Price Monitoring Extn
27th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSDeepVerge Collaboration for Water & Soil Analysis
9th Aug 20217:00 amRNSHeads of Terms signed with manufacturer in China
6th Jul 202111:55 amRNSInvestor Presentation
6th Jul 20217:00 amRNSTrading update for H1 2021
5th Jul 20219:50 amRNSHolding(s) in Company
2nd Jul 20217:00 amRNSDevelopment of real-time monitoring solution
17th Jun 202110:54 amRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.